DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property portfolio, reinforcing the company’s leadership in the development of DNA Damage Response (DDR) therapeutics for oncology.
With a robust and expanding patent estate, Aprea’s assets include four U.S. patents, one pending U.S. application, and one provisional application for its ATR inhibitor program. Globally, 19 non-U.S. patents and 16 pending applications further enhance Aprea’s intellectual property strength. Granted patents within this program provide exclusivity until 2035-2037, with pending applications potentially extending protection into 2044. Additional regulatory exclusivities of up to five years may also apply.
Aprea’s ATR inhibitor, ATRN-119, is covered under this portfolio, which encompasses proprietary compounds, pharmaceutical compositions, and methods of use. The lead candidate is currently being evaluated in the ABOYA-119 clinical trial as a monotherapy for advanced solid tumors linked to DDR-related gene mutations.
“Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response therapeutics,” said Oren Gilad, Ph.D., President and CEO of Aprea. “Intellectual property is an essential component of Aprea’s strategy, enabling us to advance first-in-class and best-in-class oncology treatments while protecting the value of our assets.”
The company has also expanded patent protections for its WEE1 kinase inhibitor program, which is supported by one pending U.S. patent application and 12 non-U.S. pending applications. Exclusivity for these patents, if granted, would extend to 2043. Regulatory extensions could secure additional protection. Aprea’s WEE1 inhibitor, APR-1051, is in the Phase 1 ACESOT-1051 clinical trial for advanced/metastatic solid tumors with specific genetic alterations.
“The WEE1 family of applications covers key aspects of the program, including proprietary compounds, pharmaceutical compositions, and methods of use,” Aprea stated, emphasizing its drive to bring breakthrough therapies to patients with difficult-to-treat cancers.
With a focus on innovation and pipeline progress, Aprea Therapeutics remains dedicated to developing life-changing oncology treatments. Its clinical trials for ATRN-119 and APR-1051 mark promising steps forward in addressing unmet medical needs and advancing the frontier of cancer care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.